Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

F-star Partners Second Early-Stage Tetravalent Bispecific Antibody with Takeda

publication date: Mar 23, 2023

F-star, a Cambridge, UK biopharma, out-licensed global rights for a novel next-gen immuno-oncology bispecific antibody to Japan’s Takeda. F-star uses its Fcab™ and mAb2 ™ platforms to discover bispecific candidates. The two companies announced a similar deal for another candidate in 2022. Two weeks ago, Sino Biopharma closed its $161 million acquisition of F-star after the deal was held up by US legislators for nine months. F-star became part of Sino Biopharm’s London subsidiary invoX, which conducts Sino Biopharm’s ex-China R&D and business development. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital